Literature DB >> 8385084

Alterations of integrin expression in human lung cancer.

S Suzuki1, T Takahashi, S Nakamura, K Koike, Y Ariyoshi, T Takahashi, R Ueda.   

Abstract

Integrins are cell-surface receptors which are involved in cell-matrix and/or cell-cell adhesion. They have been suggested to play a role in tumor invasion and metastasis. We examined the expression of various integrin subunits in normal and cancer cells of the lung using 33 human lung cancer cell lines as well as 6 lung cancer samples from which tumor cell lines could be established. This study clearly demonstrated that changes in the expression of certain integrins occur frequently in lung cancer, especially in small cell lung cancer. Loss of the alpha 1 subunit of the beta 1 integrin family appears to be the most prominent change, although loss of other integrin subunits such as alpha 2 or emergence of some integrin subunits such as alpha v can also be observed. These results suggest that changes in integrin expression may contribute to the invasive and/or metastatic behavior of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385084      PMCID: PMC5919128          DOI: 10.1111/j.1349-7006.1993.tb02851.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  24 in total

1.  Changes in integrin receptors on oncogenically transformed cells.

Authors:  L C Plantefaber; R O Hynes
Journal:  Cell       Date:  1989-01-27       Impact factor: 41.582

2.  New method to quantitate platelets adhered on biomaterials using monoclonal antibodies to human platelet membrane glycoprotein SZ-21.

Authors:  T F Xi; J C Zhang; W H Tian; C R Wang; X H Lei; H Y Wai; C G Ruan
Journal:  Biomater Artif Cells Artif Organs       Date:  1990

Review 3.  Integrins.

Authors:  E Ruoslahti
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

4.  Thrombospondin-induced adhesion of human platelets.

Authors:  G P Tuszynski; M A Kowalska
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  Two novel cell surface antigens on small cell lung carcinoma defined by mouse monoclonal antibodies NE-25 and PE-35.

Authors:  T Takahashi; R Ueda; X Song; K Nishida; M Shinzato; R Namikawa; Y Ariyoshi; K Ota; K Kato; T Nagatsu
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

6.  Beta 1 integrin expression on human small cell lung cancer cells.

Authors:  L E Feldman; K C Shin; R B Natale; R F Todd
Journal:  Cancer Res       Date:  1991-02-15       Impact factor: 12.701

7.  Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics.

Authors:  T Takahashi; Y Obata; Y Sekido; T Hida; R Ueda; H Watanabe; Y Ariyoshi; T Sugiura; T Takahashi
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

8.  Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules.

Authors:  G K Koukoulis; I Virtanen; M Korhonen; L Laitinen; V Quaranta; V E Gould
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

9.  Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.

Authors:  Y Fradet; C Cordon-Cardo; T Thomson; M E Daly; W F Whitmore; K O Lloyd; M R Melamed; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

10.  Phenotype of cells involved in mycosis fungoides and Sézary syndrome (blood and skin lesions): immunomorphological study with monoclonal antibodies.

Authors:  D Schmitt; P Souteyrand; J Brochier; J Czernielewski; J Thivolet
Journal:  Acta Derm Venereol       Date:  1982       Impact factor: 4.437

View more
  6 in total

1.  Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo.

Authors:  Qianqian Qiu; Qiongyao Wang; Changxu Deng; Yanqin Sun; Taoliang Chen; Linlang Guo; Fan Zhang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells.

Authors:  M Maemura; S K Akiyama; V L Woods; R B Dickson
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

3.  Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.

Authors:  Christian Manegold; Johan Vansteenkiste; Felipe Cardenal; Wolfgang Schuette; Penella J Woll; Ernst Ulsperger; Anne Kerber; Josef Eckmayr; Joachim von Pawel
Journal:  Invest New Drugs       Date:  2012-07-03       Impact factor: 3.850

4.  Integrin expression and ability to adhere to extracellular matrix proteins and endothelial cells in human lung cancer lines.

Authors:  M Hirasawa; N Shijubo; T Uede; S Abe
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

5.  Expression of CD44 variant isoforms in normal and neoplastic cells of the lung.

Authors:  O Washimi; R Ueda; Y Ariyoshi; M Suyama; T Seki; T Takahashi; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1994-11

6.  Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy.

Authors:  Anish Babu; Narsireddy Amreddy; Ranganayaki Muralidharan; Gopal Pathuri; Hariprasad Gali; Allshine Chen; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.